Cayuga Biotech Presents Clinical Data on Lead Product PolyP-SNP for Hemorrhage Contol

September 6, 2024

With support from Combat Casualty Care Research Program (CCCRP) and MTEC, Cayuga Biotech, Inc. has demonstrated that their lead product, a polyphosphate silica nanoparticle complex (polyP-SNP), generated thrombin 12 times faster than control, resulting in faster clotting with low potential for off-target thromboembolism. The results were recently presented at the Annual Meeting of the International Society of Thrombosis and Haemostasias (ISTH) in Bangkok, Thailand.

With support from the Combat Casualty Care Research Program and MTEC, Cayuga Biotech, Inc. demonstrated that its lead product—a polyphosphate silica nanoparticle complex (polyP-SNP)—generates thrombin 12 times faster than controls, resulting in more rapid clotting with a low risk of off-target thromboembolism. These findings were recently presented at the Annual Meeting of the International Society of Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand.

Each year, nearly 2 million people worldwide die from hemorrhage, the majority of which is preventable.The top causes of preventable death by hemorrhage are non-compressible hemorrhage sites (such as internal bleeding and from penetrating injury) and delays in hemostatic control, neither of which is adequately addressed by today’s current care model. Due to the nature of non-compressible hemorrhage sites, the complexity of clinical intervention is time consuming and delays in treatment often lead to patient death.

Data presented during the ISTH session “New strategies for reversal and prevention of bleeding” showed that polyP-SNP accelerates thrombin generation both in vitro and ex vivo—crucial for fast and effective clot formation. As an injectable drug that is inert in healthy tissue, the polyP-SNP complex circulates through the bloodstream to bleeding sites, where it boosts the body’s clotting response without triggering excessive clot formation. The activity of polyP-SNP complex is independent of FXII activation, which suggests a low potential for causing clotting in healthy tissue, a problem that has limited development for other injectable drugs to treat hemorrhage.

Cayuga plans to enroll the first patient in a Phase 1 clinical trial by the end of 2024. This trial is structured as a dose escalation safety study and includes endpoints for coagulation.

This project was selected through MTEC’s Request for Project Proposals (Solicitation #MTEC-21-06-MPAI), which sought innovative medical technologies aligned with MTEC’s Technology Focus Areas.